Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
BeiGene Ltd is a biotechnology business based in the US. BeiGene shares (BGNE) are listed on the NASDAQ and all prices are listed in US Dollars. BeiGene employs 8,600 staff and has a trailing 12-month revenue of around $1.1 billion.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $136.28 |
|---|---|
| 52-week range | $118.18 - $392.30 |
| 50-day moving average | $173.66 |
| 200-day moving average | $189.41 |
| Wall St. target price | $271.64 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-20.05 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $136.28 from 2022-09-29
| 1 week (2022-09-23) | -1.70% |
|---|---|
| 1 month (2022-08-30) | -17.67% |
| 3 months (2022-06-30) | -15.80% |
| 6 months (2022-03-30) | -33.84% |
| 1 year (2021-09-30) | -62.46% |
|---|---|
| 2 years (2020-09-30) | -52.42% |
| 3 years (2019-09-30) | 11.29% |
| 5 years (2017-09-29) | 31.72% |
| Revenue TTM | $1.1 billion |
|---|---|
| Gross profit TTM | $-447,862,000 |
| Return on assets TTM | -18.56% |
| Return on equity TTM | -45.01% |
| Profit margin | -187.65% |
| Book value | $51.08 |
| Market capitalisation | $14.6 billion |
TTM: trailing 12 months
We're not expecting BeiGene to pay a dividend over the next 12 months.
Over the last 12 months, BeiGene's shares have ranged in value from as little as $118.18 up to $392.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BeiGene's is 0.6468. This would suggest that BeiGene's shares are less volatile than average (for this exchange).
BeiGene, Ltd. , a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc. , Amgen Inc.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.